Novel anti-Ebola drug may safeguard non-human primates

Novel inhibitor protects non-human primates against Ebola | Courtesy of
Nucleotide pro-drug GS-5734, a broad-spectrum filovirus inhibitor, has been proven to offer total therapeutic protection from the Ebola Virus Disease (EVD) for primates in a study.

The high rates of deaths connected to the Ebola outbreak were partially due to a lack of effective antiviral therapies. Analysts conducted screenings for antivirals to treat Ebola, and GS-5734 (which is a pro-drug of adenine nucleotide analog) was a result.

The scientists ran in vitro activity tests of filovirus-infected human endothelial cells, macrophages and liver cells. They used PCR, quantitative GFP expression as well as immunostaining for the tests. With an LC/MS/MS and polymerase (pol) inhibition test, the scientists found the intracellular metabolism in biochemical assays.

The studies, which were blinded and placebo-controlled, involved rhesus monkeys that were infected with the virus and then given once-a-day treatments for the next 12 days with intramuscular (IM) or intravenous (IV) injection. The researchers then monitored the subjects for symptoms of Ebola.

The results showed that GS-5734 is the first small-molecule antiviral agent that shows robust therapeutic efficacy within monkey subjects infected with Ebola. Scientists are hopeful that GS-5734 can be further developed into treatments for Ebola as well as similar hemorrhagic filovirus infections.

Organizations in this story

U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) 1425 Porter Street Frederick, MD - 21702-5011

Get notified the next time we write about U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)!